Combination therapy with clk/dyrk inhibitors and bcl2 inhibitors to treat leukemia
AssigneesMemorial Sloan Kettering Cancer Center, Memorial Hospital for Cancer and Allied Diseases, Sloan-Kettering Institute for Cancer Research, BioSplice Therapeutics, Inc.
InventorsOmar Abdel-Wahab, Carine Bossard
Life of this patent
Estimating the term…
Abstract
The present disclosure provides methods for treating leukemia (e.g., AML) using a CLK/DYRK inhibitor and a B-cell lymphoma 2 (BCL2) inhibitor (e.g., venetoclax). Kits for use in practicing the methods are also provided.
Claims20
A method for preventing or treating leukemia in a subject in need thereof comprising administering to the subject an effective amount of a CLK/DYRK inhibitor and an effective amount of a BCL2 inhibitor, wherein the CLK/DYRK inhibitor is selected from cirtuvivint (SM08502) or SM09419, wherein the BCL2 inhibitor is selected from oblimersen sodium (G3139), Palcitoclax (APG-1252), and AT-101 (R-(−)-gossypol acetic acid), wherein the CLK/DYRK inhibitor and the BCL2 inhibitor are administered simultaneously and orally.
A method for preventing or treating leukemia in a subject in need thereof comprising administering to the subject an effective amount of a CLK/DYRK inhibitor and an effective amount of a BCL2 inhibitor, wherein the CLK/DYRK inhibitor is selected from CA-4948 (Emavusertib), CTX-712, AnnH75, EGCG, EHT-1610, Harmine, INDY, Leucettine L41, Lorecivivint, GNF4877, MU1210, or TCMDC-135051, wherein the BCL2 inhibitor is selected from venetoclax (ABT-199), navitoclax (ABT-263), or obatoclax (GX15-070), wherein the CLK/DYRK inhibitor and the BCL2 inhibitor are administered simultaneously and orally.
A method for preventing or treating leukemia in a subject in need thereof comprising administering to the subject an effective amount of a CLK/DYRK inhibitor and an effective amount of a BCL2 inhibitor, wherein the CLK/DYRK inhibitor is selected from CA-4948 (Emavusertib), CTX-712, AnnH75, EGCG, EHT-1610, Harmine, INDY, Leucettine L41, Lorecivivint, GNF4877, MU1210, or TCMDC-135051, wherein the BCL2 inhibitor is selected from oblimersen sodium (G3139), Palcitoclax (APG-1252), or AT-101 (R-(−)-gossypol acetic acid), wherein the CLK/DYRK inhibitor and the BCL2 inhibitor are administered simultaneously and orally.
A kit comprising (a) a BCL2 inhibitor selected from among venetoclax (ABT-199), navitoclax (ABT-263), obatoclax (GX15-070), oblimersen sodium (G3139), Palcitoclax (APG-1252), or AT-101 (R-(−)-gossypol acetic acid), (b) a CLK/DYRK inhibitor selected from among SM09419, SM08502 (Cirtuvivint), CA-4948 (Emavusertib), CTX-712, AnnH75, EGCG, EHT-1610, Harmine, INDY, Leucettine L41, Lorecivivint, GNF4877, MU1210, or TCMDC-135051, and instructions for treating leukemia.
Dependencies are inferred from the claim text.